Jasper Therapeutics

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

jobless shutter

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ANGO

DATS

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

SANA

SILO

XTIA

Crude Oil Down 1%; US Weekly Jobless Claims Decline

Analyst Color

Biotech

Health Care

Analyst Ratings

Movers

General

CLDX

Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent responses, and Phase 2b plans by late 2025.

Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors

Wall Street

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

US Stocks Down; Acuity Brands Posts Weak Revenue

Jasper Therapeutics Inc

Press Releases

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Agenus

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Biomea Fusion

Climb Bio

Caribou Biosciences

Elicio Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

IGM Biosciences

Inozyme Pharma

Invivyd

MAIA Biotechnology

Seres Therapeutics

OncoCyte

Senti Biosciences

TScan Therapeutics

Instil Bio

Tenaya Therapeutics

Vor Biopharma

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

XBiotech

HC Wainwright & Co.

JMP Securities

RBC Capital

BMO Capital

Comments

Jasper Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell